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Abstract 
Incidentally discovered adrenal masses are a common diagnostic problem. While 
computed tomography (CT) and magnetic resonance (MR) imaging can adequately 
characterize most benign or malignant adrenal masses, in some cases the results are 
indeterminate. We report and discuss a case of an adrenal metastasis with misleading 
clinical and CT features, in which an abnormal metabolic uptake detected through 
fluorine 18-fluoro-deoxy-glucose positron emission tomography (18F-FDG PET)-CT raised 
the suspicion of adrenal metastasis relatively early compared with apparently normal 
results on repeated follow-up CT examinations. 
 
Introduction 
Incidentally discovered small adrenal masses, detected through imaging
 for nonadrenal 
disease, are a common diagnostic problem. The correct identification of their benign or 
malignant nature is of critical importance, especially in patients with a known 
malignancy, since it will obviously affect treatment and prognosis. We report and discuss  
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a case of an adrenal metastasis with misleading computed tomography (CT) features and 
clinical course, in which an abnormal metabolic uptake detected through fluorine 18-
fluoro-deoxy-glucose positron emission tomography (
18F-FDG PET)-CT raised the 
suspicion of adrenal metastasis relatively early compared with apparently normal results 
on repeated follow-up CT examinations. 
Case Presentation 
A 66-year-old man came under our observation in 2007 for re-evaluation of a left adrenal mass. In 
January 2002, at the age of 61, he had undergone anterior resection of the rectum for adenocarcinoma at 
another hospital. At that time, as a part of the presurgical work-up, the patient had been submitted to 
contrast-enhanced CT examination, in order to detect distant metastases. A left adrenal mass with a 
diameter of 2.2 cm had been revealed (fig. 1). The smooth contours and homogeneous texture of the 
mass, with low attenuation values, had suggested that its nature was benign. Normal plasma levels of 
aldosterone and cortisol as well as urinary excretion of aldosterone and free corticoids had excluded 
adrenal cortex hyperfunction. Based on these features, a diagnosis of nonfunctioning adrenal adenoma 
had been made. The patient had undergone surgery, which had confirmed rectal adenocarcinoma 
(pT3pN0). 
Subsequently, serial follow-up by means of clinical assessment and biochemical tests had been 
unremarkable until March 2006, when an increase in the carcinoembryonic antigen level was observed. 
Whole-body contrast-enhanced CT showed a large mass involving the superior and middle lobes of the 
right lung, which was thought to be metastatic. However, no modifications in size and attenuation 
values of the left adrenal mass were observed, thus confirming a benign mass based on the CT features. 
The patient underwent a right-lung bilobectomy, and pathologic examination of the resected lung 
confirmed a large metastasis of adenocarcinoma. 
In November 2006, 
18F-FDG PET-CT, performed at another hospital, showed a high uptake of 
18F-
FDG in the left adrenal mass, yet without any changes in size and overall appearance. Notwithstanding 
this abnormal uptake, based on the stability in size since 2002, the adrenal lesion was still considered as 
benign. 
In July 2007, because of a rapid increase in carcinoembryonic antigen levels, the patient came to our 
attention. A 
18F-FDG PET-CT confirmed a high uptake of the metabolic tracer in the left adrenal mass, 
with a maximum Standardized Uptake Value (SUV) of 9.5. In addition, the lesion had markedly 
increased in size, and the diameter of the mass was now 4.5 cm, i.e. approximately doubled compared 
with the previous measurements (fig. 2). In order to exclude a possible pheochromocytoma, 1 month 
later scintigraphy with metaiodobenzylguanidine (MIBG) and laboratory investigations were 
performed. However, no scintigraphic alterations were found, nor did biochemical studies show 
elevation of urinary secretion of metanephrines and catecholamines, thus excluding the hypothesis of 
pheochromocytoma. 
A subsequent contrast-enhanced CT confirmed the 4.5-cm lesion in the left adrenal gland: besides 
the increase in size, the lesion showed heterogeneous enhancement on post-contrast images and low-
density internal areas, suggesting necrosis (fig. 3). 
In January 2008, the patient underwent laparoscopic left adrenalectomy and histopathologic 
examination revealed adenocarcinoma, consistent with metastatic involvement from the primary rectal 
neoplasm. 
Discussion 
Incidentally discovered small adrenal masses are common; their prevalence in autopsy 
series ranges between 1.4 and 2.9% [1]. While CT and magnetic resonance (MR) imaging 
can adequately characterize most benign or malignant adrenal masses, in some cases the  
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results are indeterminate. In such instances, functional evaluation by means of 
18F-FDG 
PET-CT may contribute to a better characterization [2]. 
Concerning CT diagnosis, criteria which allow to discriminate between benign or 
malignant lesions include size, shape, density, and vascular enhancement pattern after 
administration of i.v. contrast medium [3]. Besides being usually small (<3 cm), rounded, 
and homogeneous, a common feature of adenomas is the presence of intracytoplasmic 
lipids. For this reason, unenhanced CT densitometry can be used to help differentiate 
adrenal adenomas from metastases: adrenal masses can be diagnosed as adenomas if they 
have a CT number of 10 Hounsfield units (HU) or less on unenhanced CT, with a 
sensitivity of 71% and a specificity of 98% [4]. On the other hand, after contrast medium 
administration, both adenomas and metastases enhance early, but adrenal adenomas 
typically wash out the contrast agent more rapidly than metastases; therefore the delayed 
attenuation values at 10–15 min after contrast administration can be used to differentiate 
adenomas from malignant masses [4]. With a combination of unenhanced and delayed 
enhanced CT, most adrenal masses can be correctly categorized (sensitivity 96–98%; 
specificity 61–92%, accuracy 81–96%) [3, 4]. 
Based on similar criteria, MR imaging can also evaluate the morphological and signal 
intensity features as well as the fat component of an adrenal mass, thus allowing to 
reliably differentiate benign from malignant masses in most cases, with an overall 
accuracy of 94% (89% sensitivity
 and 99% specificity) [5]. 
However, approximately 30% of adenomas are lipid-poor, and conversely small 
metastases appear frequently homogeneous on contrast-enhanced CT. Therefore, 
notwithstanding the abovementioned criteria, both on CT and MR studies the 
attenuation and signal intensity values as well as the morphological features of adenomas 
may overlap with those of metastases in 20–30% [2]. 
A few reports and studies in the literature have suggested that 
18F-FDG PET-CT is 
useful to differentiate benign from malignant adrenal lesions, with sensitivity and 
specificity ranging from 92 to 100% and from 80 to 100%, respectively [6–11]. 
Hemorrhage, necrosis, small size of the lesion, and metastases from non-
18F-FDG-avid 
tumors – such as neuroendocrine tumors – are reported to be the most common causes of 
a false-negative scan. Conversely, mildly to moderately increased FDG uptake may 
occasionally be seen in benign lesions such as some pheochromocytomas and adenomas, 
with consequent false positive results. The degree of metabolic uptake of adenomas on 
PET-CT is in fact variable and has still not been analyzed thoroughly in the literature, 
although the functional state of adenomas is reported to be the principal factor 
determining the intensity of 
18F-FDG uptake [8]. 
Concerning PET-CT exams, there is still some debate about which is the best method 
for assessing adrenal 
18F-FDG uptake. For some authors, semiquantitative analysis 
performed by SUV and SUV ratio – i.e. adrenal nodule SUV/liver SUV – might be used to 
accurately differentiate benign from malignant adrenal lesions. Metser et al. [9] found 
that a SUV cutoff of 3.1 resulted in a sensitivity of 98.5% and specificity of 92% for 
differentiating adenomas from malignant lesions. Similar results were found by Brady et 
al. [10] by combining mean attenuation >10 HU and a maximum SUV >3.1 (97.3% 
sensitivity, 86.2% specificity, 90.5% accuracy). In contrast, Jana et al. [11] showed that 
there were no significant differences between visual interpretation and SUV 
measurement. According to Tessonier et al. [6], an adrenal 
18F-FDG uptake higher than  
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that of the liver on visual interpretation is considered suggestive of malignancy and more 
accurate than maximum SUV value alone. 
In the current case, both the imaging features of the adrenal lesion and the clinical 
course were quite unusual. The mass remained absolutely stable in size and morphology 
for almost 5 years (from January 2002 through November 2006). Stability in size for more 
than 1 year of follow-up is usually considered a criterion of benign disease. Thus, only the 
first PET-CT examination revealed an unexpected finding, i.e. the increased metabolic 
uptake, whereas the CT findings were still unmodified. Indeed, the CT features on 
previous exams met all the morphological criteria of a benign lesion even at the time of 
the first abnormal 
18F-FDG PET-CT exam. Alternatively, the hypothesis of a metastasis 
occurring in an adrenal gland with a pre-existing adrenal adenoma
 (so-called ‘collision 
tumors’) cannot completely be excluded [12]. However, the presence of a slow-growing 
metastasis is more likely, due to the 
18F-FDG uptake demonstrated since 2006. 
According to our experience from this case, in a patient with a known primary cancer 
further evaluation by means of image-guided biopsy should be considered for any 
nonhyperfunctioning adrenal mass showing an abnormal FDG uptake, notwithstanding 
the possibility that its CT features may appear benign, whenever early metastatic tumor 
recognition is clinically required. Percutaneous image-guided biopsy (by CT or less 
frequently by transabdominal ultrasound guidance) is an effective and widely accepted 
procedure for characterizing those lesions exhibiting ambiguous features that may remain 
indeterminate by imaging, with a reported accuracy of about 90% and a complication rate 
of about 2.8–4.3% [13]. Fine-needle aspiration biopsy of the adrenal glands under 
endoscopic ultrasound guidance has also been developed and represents an innovative 
application which appears to play an increasing role in the near future for the evaluation 
of adrenal lesions [14]. 
In patients with colorectal cancer, the clinical course and the prognosis may vary 
greatly (the 5-year survival rate ranges from 10 to 90%) depending on many factors, such 
as tumor node metastasis stage, histologic type, and tumor grade [15]. Although 
colorectal carcinoma is known to be generally less aggressive compared with other 
abdominal and gastroenteric (G.E.) tract tumors, the extremely slow progression of the 
metastatic tumor makes this case quite unusual. In fact, the adrenal metastasis not only 
exhibited benign features on serial CT scans performed from 2002 through 2006 but also 
remained stable in size for almost 5 years. PET-CT evaluation, instead, allowed the early 
detection of a functional abnormality – i.e. the increased metabolic FDG uptake – before 
any morphological change occurred, and eventually led to the correct diagnosis of adrenal 
metastasis. 
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Fig. 1. Contrast-enhanced CT (January 2002). CT examination of the upper abdomen, in the portal 
phase of the study, shows a well-circumscribed rounded hypodense mass with a diameter of 2.2 cm in 
the medial portion of the left adrenal gland (arrow). The low attenuation and homogeneous texture of 
the mass, together with the small size and well-defined margins, are consistent with an adenoma by 
established CT criteria. The right adrenal gland is normal. 
 
 
 
Fig. 2. 
18F-FDG PET-CT (July 2007). Unenhanced CT (a), 
18F-FDG PET (b) and fused images (c) show 
high 
18F-FDG uptake in the left adrenal mass (arrow), with a maximum SUV of 9.5. The lesion is 
markedly increased in size, measuring 4.5 cm, i.e. approximately doubled compared to previous 
measurements. 
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Fig. 3. Contrast-enhanced CT (December 2007). CT examination performed a few months later 
confirmed the presence of an irregular 4.5-cm lesion in the left adrenal gland (arrow), inhomogeneous 
with low-density internal areas suggesting necrosis, a finding that is most consistent with malignancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Case Rep Oncol 2010;3:416–422 
DOI: 10.1159/000322508 
Published online: 
November 17, 2010
© 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
422
References 
1  Mansmann G, Lau J, Balk E, Rothberg M, Miyaki Y, Bornstein SR: The clinically inapparent adrenal mass: 
update in diagnosis and management. Endocr Rev 2004;25:309–340. 
2  Dunnick NR, Korobkin M: Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol 
2002;179:559–568. 
3  Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR: Characterization of adrenal 
masses using unenhanced CT: an analysis of the CT literature. AJR Am Roentgenol 1998;171:201–204. 
4  Kamiyama T, Fukukura Y, Yoneyama T, Takumi K, Nakajo M: Distinguishing adrenal adenomas from 
nonadenomas: combined use of diagnostic parameters of unenhanced and short 5-min dynamic enhanced CT 
protocol. Radiology 2009;250:474–481. 
5  Hönigschnabl S, Gallo S, Niederle B, Prager G, Kaserer K, Lechner G, Heinz-Peer G: How accurate is MR 
imaging in characterisation of adrenal masses: update of a long-term study. Eur J Radiol 2002;41:113–122. 
6  Tessonnier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, Mancini J, Conte-Devolx B, Henry JF Mundler O, 
Taïeb D: Does 18F-FDG PET-CT add diagnostic accuracy in incidentally identified non-secreting adrenal 
tumours? Eur J Nucl Med Mol Imaging 2008;35:2018–2025. 
7  Boland GW, Blake MA, Holalkere NS, Hahn PF: PET/CT for the characterization of adrenal masses in patients 
with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am Roentgenol 
2009;192:956–962. 
8  Elaini AB, Shetty SK, Chapman VM, Sahani DV, Boland GW, Sweeney AT, Maher MM, Slattery JT, Mueller 
PM, Blake MA: Improved detection and characterization of adrenal disease with PET-CT. Radiographics 
2007;27:755–767. 
9  Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E: 18F-FDG PET/CT in the evaluation of 
adrenal masses. J Nucl Med 2006;47:32–37. 
10  Brady MJ, Thomas J, Wong TZ, Franklin M, Ho LM, Paulson EK: Adrenal nodules at FDG PET/CT in patients 
known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology 
2009;250:523–530. 
11  Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD: FDG-PET and CT characterization of adrenal lesions in 
cancer patients. Eur J Nucl Med Mol Imaging 2006;33:29–35. 
12  Schwartz LH, Macari H, Huvos AG, Panicek DM: Collision tumors of the adrenal gland: demonstration and 
characterization on MR imaging. Radiology 1996;201:757–760. 
13  Harisinghani MG, Maher MM, Hahn PF, Gervais DA, Jhaveri K, Varghese J, Mueller PR: Predictive value of 
benign percutaneous adrenal biopsies in oncology patients. Clin Radiol 2002;57:898–901. 
14  Lumachi F, Borsato S, Brandes AA, Boccagni P, Tregnaghi A, Angelini F, Favia G: Fine-needle aspiration 
cytology of adrenal masses in noncancer patients: clinicoradiologic and histologic correlations in functioning 
and nonfunctioning tumors. Cancer 2001;93:323–329. 
15  Zlobec I, Lugli A: Prognostic and predictive factors in colorectal cancer. J Clin Pathol 2008;61:561–569. 